Sage’s Biogen-Partnered Essential Tremor Drug Fails In Phase II
Companies Discontinue Development In ET
For Sage, the mid-stage failure of SAGE-324 in essential tremor is its second setback in a year full of clinical trial readouts. For Biogen, it highlights a lack of later-stage pipeline prospects.
